Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Get Help Today

Looking for help or additional information? Contact us today.
First Name:
Last Name:
Email:
Phone:
Zip Code:
Comments:
Please enter the number below:
3163
Conditions: Mesothelioma
Start Date: February 1, 2004
Phase: Phase II
Status: Completed
NCT ID: NCT00137826
Study Type: Interventional
Intervention: Drug: Erlotinib|Drug: Bevacizumab
Study Design: Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Results: No Results Available
Sponsors: Dana-Farber Cancer Institute|Massachusetts General Hospital|University of Chicago
Ages: Adult|Senior
Enrollment: 37
Funded By: Other
First Received: August 29, 2005
End Date: July 1, 2009
Last Updated: October 30, 2009
Last Verified: October 1, 2009